Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

David Chang, ESCRS 2019 – Light adjustable IOLs

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 23rd 2019

David Chang (Altos Eye Physicians) discusses the latest developments in light-adjustable IOLs and which patients they are likely to benefit.

Questions:
1. What are the major causes of unsatisfactory visual outcomes following intraocular lens (IOL) implantation and why is there a need for a light-adjustable IOL?
2. Could you give us a brief overview of the technology behind light-adjustable IOLs?
3. What adjustable IOL technologies are currently being developed?
4. Which patients are most likely to benefit from light-adjustable IOLs?

Support: No funding was received in the production of this video.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup